Ixico reports higher interim revenue, larger order book

(Sharecast News) - Ixico reported higher interim revenue and a larger order book on Tuesday, as new contract wins, extensions and increased biomarker analysis activity supported growth in the first half.

The AIM-traded neuroscience imaging and biomarker analytics company said revenue rose 23% to £3.9m for the six months ended 31 March, from £3.2m a year earlier.

Gross margin improved to 53% from 50%.

The order book increased to £18.1m, up 38% from £13.1m at the same point last year and 31% ahead of the £13.8m reported at the end of September 2025.

Ixico reported a loss before interest, tax, depreciation and amortisation of £0.5m, narrowed from a £0.7m loss a year earlier, as higher revenue was partly offset by the full-period impact of investment in its Innovate, Lead, Scale strategy.

Cash stood at £1.7m at the period end, compared with £5.0m a year earlier.

After the period ended, Ixico completed a £10m capital raise, or £9.4m after costs, to support its TechBio strategy, focused on integrating and partnering its IXI platform across contract research organisations, clinical trial management and healthcare providers.

The company said it had signed a commercial agreement with Medidata, part of Dassault Systèmes, under which IXI will augment Medidata's clinical trials technology platform.

It also extended operational imaging site support into US and Asian time zones, strengthening its global reach.

Ixico said it had made progress on its technology and product roadmap in Alzheimer's and Parkinson's disease, increasing commercial opportunities.

It also won projects across therapeutic areas, clinical phases including Phase 2 and Phase 3, and customer types, including a growing number of diagnostic companies.

After the period ended, the company deployed version 10 of its IXI AI-driven platform, increasing data upload and analysis speeds.

Chief executive Bram Goorden said the first half had seen strong revenue growth, improved operational leverage and a significantly larger order book.

"While we continue to invest for growth, we have reduced our EBITDA loss year-on-year, demonstrating progress towards profitability," he said.

Goorden added that the recent capital raise was intended to increase value from the IXI platform as a premium technology, describing the company as being "in the middle of the current surge in research into neurodegenerative diseases".

At 1305 BST, shares in Ixico were up 33.33% at 9p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

Ixico